D. Mavroudis

FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG)

John Souglakos, N. Androulakis, K. Syrigos et al. · British Journal of Cancer · 2006 · 399 citations · Full text

Molecular Detection of Cytokeratin-19–Positive Cells in the Peripheral Blood of Patients With Operable Breast Cancer: Evaluation of Their Prognostic Significance

Aliki Stathopoulou, Ioannis G. Vlachonikolis, D. Mavroudis et al. · Journal of Clinical Oncology · 2002 · 340 citations

Comparison of EGFR and K-RAS gene status between primary tumours and corresponding metastases in NSCLC

Aristea Kalikaki, Anastasios Koutsopoulos, Maria Trypaki et al. · British Journal of Cancer · 2008 · 207 citations · Full text

Six versus 12 months of adjuvant trastuzumab in combination with dose-dense chemotherapy for women with HER2-positive breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HORG)

D. Mavroudis, Emmanouil Saloustros, N. Malamos et al. · Annals of Oncology · 2015 · 162 citations

Breast Oncology, Oncology, Dose-dense Chemotherapy +6

Trastuzumab decreases the incidence of clinical relapses in patients with early breast cancer presenting chemotherapy-resistant CK-19mRNA-positive circulating tumor cells: results of a randomized phase II study

Vasilis Georgoulias, V. Bozionelou, Sofia Agelaki et al. · Annals of Oncology · 2012 · 147 citations · Full text

Tumor Biology, Breast Oncology, Early Breast Cancer +9